Insilico Licenses ISM4808 To TaiGen Biopharma
Insilico Medicine and TaiGen Biotechnology announced an exclusive out-licensing deal granting TaiGen Greater China rights to ISM4808, a PHD inhibitor, with Insilico eligible for upfront, milestone and tiered royalty payments totaling a two‑digit million-dollar package. Nominated in 2022 and published in January 2024, ISM4808 showed potent preclinical efficacy, favorable ADME/PK and received IND clearance from China’s CDE in 2023, targeting the HIF‑α pathway for CKD-related anemia.
Key Points
- 1Grants TaiGen exclusive Greater China rights to ISM4808, with Insilico earning two‑digit million payments.
- 2Highlights AI-driven discovery: ISM4808 designed via Chemistry42 and published January 2024.
- 3Suggests faster lead generation and potential oral PHD inhibitor option for CKD-related anemia development.
Scoring Rationale
Official commercialisation of an AI-designed drug program signals high relevance and credibility, limited by a single candidate and regional scope.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems